Contribute Try STAT+ Today

Gilead’s board hired CEO Dan O’Day a year ago to look for new areas of growth for the $22 billion biotech. On Monday, the company announced that it would spend $4.9 billion to purchase Forty Seven, a developer of new cancer drugs.

The deal is likely to be met warmly by investors, though some may balk at the price: Gilead is paying double what shares of Forty Seven traded at before deal negotiations were reported by Bloomberg last week. Shares in Gilead rose 4.5% in early morning trading. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.